In conclusion, we provide a powerful tool for the development of the AD drugs by our network-based drug-screening platform through the integration of mathematical modeling and the pathological features of human iCOs, which are derived from the sporadic AD patients. With further generation of the ...
The First Layer in the framework is responsible for detecting AD patients from CN and MCI patients. To determine the smallest number of features that produces the most accurate results, we performed a set of experiments using different combination of modalities. Table2shows the performance obtained ...
At the same time, declines in sensory abilities, and a wide range of brain functions including sensory processing, attention, decision-making, and memory, are consistent with the early symp- toms exhibited by AD patients [39]. Appl. Sci. 2023, 13, 12030 the MCI and AD groups. As can ...